

Antimicrobials, antimicrobial resistance and antimicrobial susceptibility testing

The basics

CRL Training course
in AST
Copenhagen, Denmark
23 - 27th Feb. 2009

What is an antibiotic?

Antibiotic is a substance **produced by a microorganism**, that have the capacity, in dilute solution, to **selectively inhibit or kill** other microorganisms (Paul Vuillemin 1941).

Some of the most toxic substances in the world
0.001 – 4 mg/L

Note the minimum effects on eucaryotic cells

Definition of an antimicrobial agent

Antimicrobial agents is a broader term -
Referring to **any substance** that can **affect microbial life**, including synthetic and semi-synthetic compounds and substances without selective toxicity (e.g. disinfectants)

Origin of antimicrobial classes

| Class | Antimicrobial agent(s) | Producing organism(s) | Yr of isolation |
|-------------------------|--------------------------------------|--|-----------------|
| β-Lactam antibiotics | Natural penicillins | <i>Penicillium notatum</i> , <i>Penicillium chrysogenum</i> | 1929, 1940 |
| | Cephalosporin C | <i>Cephalosporium acremonium</i> | 1945, 1953 |
| | Imipenem | <i>Streptomyces cattleya</i> | 1976 |
| | Aztreonam | <i>Gluconobacter</i> spp., <i>Chromobacterium violaceum</i> | 1981 |
| Glycopeptides | Vancomycin | <i>Amycolatopsis orientalis</i> | Mid-1950s |
| | Teicoplanin, avoparcin | <i>Amycolatopsis coloradensis</i> subsp. <i>labeda</i> | 1975 |
| Macrolides | Erythromycin | <i>Streptomyces erythraeus</i> | 1952 |
| | Spiramycin | <i>Streptomyces ambofaciens</i> | 1955 |
| Lincosamides | Lincomycin | <i>Streptomyces lincolnensis</i> | 1963 |
| Streptogramins | Streptogramins A and B | <i>Streptomyces diastaticus</i> | 1953 |
| | Virginiamycins A and B | <i>Streptomyces virginiae</i> | 1955 |
| Tetracyclines | Chlortetracycline | <i>Streptomyces aureofaciens</i> | 1948 |
| | Oxytetracycline | <i>Streptomyces rimosus</i> | |
| Phenicol | Chloramphenicol | <i>Streptomyces venezuelae</i> | 1947 |
| Aminoglycosides | Streptomycin | <i>Streptomyces griseus</i> | 1943 |
| | Neomycin | <i>Streptomyces fradiae</i> | 1949 |
| | Kanamycin | <i>Streptomyces kanamyceticus</i> | 1957 |
| | Gentamicin | <i>Micromonospora purpurea</i> | 1963 |
| | Tobramycin | <i>Streptomyces tenebrarius</i> | 1967 |
| | Spectinomycin | <i>Streptomyces spectabilis</i> | 1961 |
| Aminocyclitols | Spectinomycin | <i>Streptomyces spectabilis</i> | 1961 |
| Pleuromutilins | Tiamulin | <i>Pleurotus</i> spp. | |
| Polypeptide antibiotics | Polymyxin B | <i>Bacillus polymyxa (aerosporus)</i> | 1947 |
| | Polymyxin E (colistin) | <i>Bacillus polymyxa</i> subsp. <i>colistinus</i> | 1949 |
| | Bacitracin | <i>Bacillus licheniformis</i> | 1943 |
| Sulfonamides | Prontosil, sulfamethoxazole, etc. | Synthetic | 1935 |
| | Trimethoprim | Trimethoprim | Synthetic |
| Quinolones | Nalidixic acid | Synthetic | 1962 |
| Fluoroquinolones | Flumequine, enrofloxacin, etc. | Synthetic | 1973 |
| | Oxazolidinones | Linezolid | Synthetic |

Bactericidal vs. Bacteriostatic antimicrobials

| Class | Origin | Activity |
|-----------------|--|----------------|
| Aminoglycosides | <i>Streptomyces, Micromonospora sp</i> | Bactericidal |
| Cephalosporins | <i>Cephalosporium sp</i> | Bactericidal |
| Macrolides | Various Actinomycetes | Bacteriostatic |
| Penicillins | <i>Penicillium sp</i> | Bactericidal |
| Phenicol | <i>Streptomyces venezuelae*</i> | Bacteriostatic |
| Quinolones | Synthetic | Bactericidal |
| Rifamycins | <i>Amycolatopsis mediterranei</i> | Bactericidal |
| Sulfonamides | Synthetic | Bacteriostatic |
| Tetracyclines | <i>Streptomyces sp</i> | Bacteriostatic |

Table 1. Antimicrobial agents approved for use in human and veterinary medicine.


| Antimicrobial class/drug | Examples of antimicrobials used in human medicine | Examples of antimicrobials used in veterinary medicine or as growth promoters |
|---|---|---|
| <i>Antimicrobial classes classified as 'critically important' for human health by the WHO</i> | | |
| Aminoglycosides | Amikacin, arbekacin, gentamicin, kanamycin, netilmicin, neomycin, tobramycin, streptomycin | Amikacin, apramycin, gentamicin, neomycin, streptomycin, dihydrostreptomycin, kanamycin, framycetin, paromomycin (aminosidine) |
| Ansamycins | Rifabutin, rifampin, rifaximin | Rifampicin |
| Carbapenems and other penems | Ertapenem, faropenem, imipenem, meropenem, doripenem | None approved or known to be used |
| Cephalosporins, third generation | Cefixime, cefotaxime, cefpodoxime, ceftazidime, ceftiozime, cefoperazone, cefoperazone/sulbactam, ceftriaxone | Cefpodoxime, ceftiofur, cefoperazone, cefovecin |
| Cephalosporins, fourth generation | Cefipime, cefpirome, cefoselis | Cefquinome |
| Lipopeptides | Daptomycin | None approved or known to be used |
| Glycopeptides | Teicoplanin, vancomycin | Avoparcin* |
| Macrolides, including 14-, 15-, 16-membered compounds, ketolides | Azithromycin, clarithromycin, erythromycin, midecamycin, roxithromycin, spiramycin, telithromycin | Erythromycin, pirlimycin, spiramycin, tylosin, tulathromycin, kitasamycin, cleandomycin, tilmicosin, jasamycin |
| Oxazolidinones | Linezolid | None approved or known to be used |
| Penicillins, amino | Ampicillin/amoxicillin, ampicillin/sulbactam, amoxicillin/davulanate, piperacillin, piperacillin/tazobactam | Ampicillin/amoxicillin, ampicillin/sulbactam, amoxicillin/davulanate |
| Penicillins, natural | Penicillin G, penicillin V | Penicillin G, penicillin V |
| Quinolones | Gnoxacin, nalidixic acid, piperidemic acid, ciprofloxacin, enoxacin, gatifloxacin, gemifloxacin, levofloxacin, lomefloxacin, moxifloxacin, norfloxacin, ofloxacin, sparfloxacin | Nalidixic acid, oxolinic acid, flumequine, pipemidic acid, danofloxacin, difloxacin, enrofloxacin, lbafloracin, marbofloxacin, sarafloxacin, orbifloxacin, moxifloxacin |
| Streptogramins | Quinupristin/dalfopristin, pristinaamycin | Virginiamycin† |
| Drugs used solely to treat tuberculosis or other mycobacterial disease | Cycloserine, ethambutol, ethionamide, isoniazid, para-aminosalicylic acid, pyrazinamide | None approved or known to be used |
| <i>Antimicrobial classes classified as 'highly important' for human health by the WHO</i> | | |
| Cephalosporins, first generation | Cefazolin, cephalexin, cephalothin, cephadrine | Cephalothin, cephalonium, cephalexin, cefadroxil, cefazolin |
| Cephalosporins, second generation | Cefador, cefamandole, cefuroxime, loracarbef | Cefuroxime |
| Cephameycins | Cefotetan, ceftioxin | None approved or known to be used |
| Clofazimine | Clofazimine | None approved or known to be used |
| Monobactams | Aztreonam | None approved or known to be used |
| Penicillins, amino | Medillinam | None approved or known to be used |
| Penicillins, antipseudomonal† | Azlocillin, carbenicillin, mezlocillin, ticarcillin, ticarcillin/davulanate | None approved or known to be used |
| Polymyxins | Polymyxin B, colistin | Polymyxin B, colistin |

*Up until 2000, avoparcin was used extensively as a growth promoter around the world (except in North America).

†Up until 2000, virginiamycin was used extensively as a growth promoter in Europe. It is still used extensively in North America, Australia and many other parts of the world.

‡Extensively used for growth promotion and/or control of coccidiosis around the world.

Targets of antimicrobial action



Modes of antimicrobial action

- Inhibition of cell wall synthesis
- Inhibition of DNA synthesis
- Inhibition of protein synthesis
- Inhibition of RNA synthesis
- Inhibition of folic acid synthesis
- DNA breakage
- Disruption of osmotic integrity

Note - A limited number of targets

What is antibiotic resistance?

Microbiological definition:

- Resistance is the property of a bacterial strain to survive at higher antibiotic concentrations compared with most other members of the same species (Wildtypes)

Clinical definition:

- Resistance is the ability of a bacterial strain to survive antimicrobial therapy

What is intrinsic resistance?


Resistance due to a structural or functional trait allowing tolerance by all members of a bacterial group (species, genus or even larger group)

- Low affinity of the target
- Impermeability
- Active exporters
- Enzymatic degradation

Example of intrinsic resistance


Cefotaxime susceptibility in *E. coli* and *Acinetobacter baumannii*

Cefotaxime / *Escherichia coli*
Antimicrobial wild type distributions of microorganisms - reference database
EUCAST



MIC
Epidemiological cut-off: WT ≤ 0.25 mg/L
3781 observations (11 data sources)
Clinical breakpoints: S ≤ - mg/L, R > - mg/L

Cefotaxime / *Acinetobacter baumannii*
Antimicrobial wild type distributions of microorganisms - reference database
EUCAST




MIC
Epidemiological cut-off: -
861 observations (2 data sources)
Clinical breakpoints: S ≤ - mg/L, R > - mg/L

Two types of acquired resistance

Mutation (endogenous, vertical)

Gene transfer (exogenous, horizontal)

- Transformation (free DNA)
- Transduction (with phages)
- Conjugation (plasmids – active process)



What is cross-resistance

Resistance to **two related** (avoparcin / vancomycin) or **unrelated** drugs (erythromycin / lincosamides) is due to a **single biological mechanism**

Mechanisms of resistance

- Inactivation of the drug
 - Penicillins, aminoglycosides
- Target modification
 - Tetracyclines, fluoroquinolones
- Drug trapping or titration - hyperproducers
 - Penicillins, sulphonamides
- Impermeability
 - Broad range of antibiotics (only reduced susceptibility)
- Active efflux
 - Disinfectants, metals

How do we measure antimicrobial susceptibility


Agar diffusion method

- Disk (tablet) methods
- E-test (quantitative)



Dilution methods


- Micro broth dilution - Liquid media (quantitative)
- Macro broth dilution - Liquid media (quantitative)
- Agar dilution - Solid media (quantitative)



MIC

Correlation between MIC and DD

MIC and inhibition zones should correlate for each antimicrobial for both slow growing and fast growing bacteria



Guidelines

International standards describe the methods (DD and MIC) in detail: media, inoculum, incubation, etc. - e.g. CLSI (Clinical and Laboratory Standards Institute)

- CLSI has defined QC reference strains and corresponding the acceptable QC results
- CLSI recommends clinical breakpoints for interpretation

Resistant: Treatment failure can be expected


Sensitive: Successful treatment can be expected

Intermediary: Treatment is possible if the infection is in bodysites where the antimicrobial is concentrated. Primarily a bufferzone to avoid misinterpretation

Epidemiological Cut Off Values

Defined by EUCAST (The European Committee on Antimicrobial Susceptibility Testing – www.eucast.org)

- for monitoring purpose only, no relation to clinical data
- defined by the wild type distribution of the bacteria
- all isolates with MICs above the WT distribution are called resistant



WT = Wild type organisms, i.e micro-organisms without phenotypically detectable antimicrobial resistance to the drug in question
S = Susceptible; I = Intermediate; R = Resistant

Techniques - Pros and Cons

MIC determination

- Golden standard for AST
- Data more reproducible
- Better separation of R/S
- More information
- Expensive
- Only pure cultures
- Contaminations more difficult to detect

Diffusion techniques

- Cheaper
- Primary material
- See contaminations
- Quick screening (4 hours)
- Qualitative information
- Less reproducible data
- Standardisation more difficult

Disk diffusion - Considerations

Disk diffusion methods gives reliable and reproducible data, if standardization and quality assurance is used

- Use international guidelines (e.g. CLSI)
- Standardize the method (inoculum, media, incubation, reading of results)
- Use ring tests (define criteria for acceptance, evaluate results)
- Use reference strains for method validation
- Act on deviations on the QC-strain
- Document corrective actions

Standardisation

All methods are extremely sensitive to variations in performance

Factors that influence the result:


- Size of inoculum
- Contents and acidity (pH) of the broth or agar
- Incubation time and temperature
- Reading procedures

Moreover, for the *diffusion methods*:

- Diffusion rate of the antimicrobial into the agar
- Depth of the agar
- Dryness of the agar
- Growth rate of the bacteria



WHO Global
Salm-Surv
*Building Global Capacity for the
Surveillance and Detection of Resistance
and other Infectious Control Issues*
www.who.int/salmsurv



Thank you!

Rene Hendriksen (rshe@food.dtu.dk)